IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

CHIESI FARMACEUTICI S.P.A., and AMRYT ENDO, INC., **Plaintiffs,** **v.** **TEVA PHARMACEUTICALS, INC.,** **Defendant.**	**Civil Action No. 24-441-CFC**

CONSENT JUDGMENT

Plaintiffs Chiesi Farmaceutici S.p.A. and Amryt Endo, Inc. (collectively, "Chiesi" or "Plaintiffs") and Defendant Teva Pharmaceuticals Inc. ("Teva" or "Defendant"), the parties in the above-captioned action, hereby stipulate and consent to entry of judgment and an injunction in this action as follows:

IT IS this 26th day of July, 2024:

ORDERED, ADJUDGED, AND DECREED as follows:

1. This Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties for purposes of this action only, including as set forth below in Paragraph 6 of this Consent Judgment.

2. As used in this Consent Judgment, the term "Teva ANDA Product" means a drug product manufactured, imported, sold, offered for sale,

marketed, or distributed pursuant to Abbreviated New Drug Application No. 217507 in or for the United States of America, including its territories, possessions, and the Commonwealth of Puerto Rico.

3. As used in this Consent Judgment, the term "Patents-in-Suit" means U.S. Patent Nos. 8,329,198; 8,535,695; 9,265,812; 9,566,246; 10,238,709; 10,695,397; 11,052,126; 11,141,457; 11,338,011; 11,510,963; 11,857,595; 11,890,316; and 11,969,471.

4. Until expiration of the Patents-in-Suit, Teva, including any of its successors and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third party on its behalf, by making, having made, using, selling, offering to sell, importing, or distributing of the Teva ANDA Product in or for the United States of America, including its territories, possessions, and the Commonwealth of Puerto Rico, except as specifically authorized by Chiesi, and is further enjoined from assisting or cooperating with any third parties in connection with any infringement of the Patents-in-Suit by any such third parties in connection with making, having made, using, selling, offering to sell, importing, or distributing any octreotide-containing drug product that references New Drug Application No. 208232 in or for the United States of America, including its territories, possessions, and the Commonwealth of Puerto Rico, except as otherwise specifically authorized by Chiesi.

5. Compliance with this Consent Judgment may be enforced by Chiesi, Chiesi USA, Inc., or any of their respective successors in interest or assigns.

6. This Court retains jurisdiction to enforce the terms of this Consent Judgment and to enforce and resolve any disputes related thereto.

7. All claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed with prejudice and without costs, disbursements, or attorney fees to any party.

8. Nothing herein prohibits or is intended to prohibit Teva from maintaining any "Paragraph IV Certification" pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) or pursuant to 21 C.F.R. § 314.94(a)(12) with respect to the Patents-in-Suit.

9. Nothing herein restricts or is intended to restrict the U.S. Food and Drug Administration from approving Abbreviated New Drug Application No. 217507 or the Teva ANDA Product.

CHIEF UNITED STATES DISTRICT JUDGE

Dated: July 25, 2024

/s/ Kelly E. Farnan
Kelly E. Farnan (#4395)
Sara M. Metzler (#6509)
Richards, Layton & Finger, P.A.
One Rodney Square
920 N. King Street
Wilmington, DE 19801
(302) 651-7700
farnan@rlf.com
metzler@rlf.com

Attorneys for Plaintiffs Chiesi Farmaceutici S.p.A. and Amryt Endo, Inc.

/s/ Karen E. Keller
Karen E. Keller (#4489)
Shaw Keller LLP
1105 N Market St.
Wilmington, DE 19801
302-298-0700
Kkeller@shawkeller.com

Attorneys for Defendant Teva Pharmaceuticals, Inc.